Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. Sandoz is a subsidiary of Novartis, now headquartered in Germany. The subsidiary was formerly a collection of companies under the Novartis Generics umbrella name, but a major rebranding and reorganisation process began in 2002.

Sandoz is currently the second largest generic manufacturer in the world, behind Teva. The company completed its acquisition of Hexal and Eon Labs in June 2005, in one of the generic industry's largest mergers to date. The combined company has a new HQ in Germany.

Europe is the company's largest market, with 58% of total sales in 2006. Sales generated in the USA accounted for 26% of Sandoz' total sales in 2006.

Major production sites are in Austria, the USA, Germany and Slovenia. Around two thirds of the company's workforce is based in Europe. The US subsidiary was formerly known as Geneva Pharmaceuticals, owned by Novartis since 1979. Novartis purchased the major Slovenian producer, Lek, in 2003. Lek has a major presence in the CEE region.

Sandoz is a frontrunner in the development of biosimilar products. Its human growth hormone product, Omnitrope, was approved in 2006, and the company has followed this with European approval of EPO in 2007. Lek began constructing a new biotech plant in Slovenia in September 2006, and a new injectables facility has recently been announced in Canada.